Business Wire

NEUSTAR

23.3.2021 10:02:05 CET | Business Wire | Press release

Share
Neustar: New Ponemon Institute Report highlights value of threat data feeds in improving organisations’ security posture

Threat data feeds can help organisations strengthen their cybersecurity posture, according to a new report from Ponemon Institute, the pre-eminent research centre dedicated to privacy, data protection and information security policy. Neustar Inc. , a global information services and technology company and leader in identity resolution, sponsored the independently conducted study on the state of threat feed effectiveness in the United States and the United Kingdom.

As cyberthreats proliferate, many organisations are using threat feeds with insights from domain name system (DNS) data to help IT security teams better understand threats and block malicious activity. A large majority (79%) of the more than 1,000 security professionals participating in the Ponemon study said threat data feeds were essential to their organisation’s ability to achieve a strong cybersecurity posture, and more than half (55%) rate the quality of their threat feeds’ ability to pinpoint cyberthreats as very high.

Study participants said threat data feeds offer a number of benefits: they add unique data to better inform security (71%), increase preventive blocking to ensure a better defence (63%), reduce the mean time to detect and remediate an attack (55%), and reduce the time spent researching false positives (51%).

However, more than half (56%) of respondents also said threat feeds deliver data that is often too voluminous and/or complex to provide timely and actionable intelligence.

Neustar’s UltraThreat Feeds service addresses these issues by drawing on proprietary data derived from the company’s expansive authoritative and recursive DNS services, DDoS mitigation solutions, OneID system and IP geolocation data. This service, which processes the data and outputs the observations and key insights, has been designed by Neustar’s renowned DNS experts, as well as leading academic researchers. UltraThreat Feeds data, provided as either near real-time threat data feeds or via API calls (JSON format), enable organisations to detect potential threats and identify and stop bad traffic, both inbound and outbound.

“Facing an increase in the volume, sophistication and diversity of threats, enterprises are investing significant resources into threat intelligence solutions to bolster their cyber defences,” said Michael Kaczmarek, senior vice president at Neustar. “Solutions that deliver real-time information on active threats, like Neustar’s UltraThreat Feeds service, can quickly deliver ROI across many layers of an organisation’s defence by improving the performance of network and application security tools – such as SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls – which require threat data to effectively detect and block malicious actors.”

Each of the organisations surveyed by Ponemon faced an average of 28 cyberattacks in the past two years. On average, respondents said 38% of these cyberattacks were not stopped because security teams lacked timely and actionable data from their data feeds. Respondents also reported that half (50%) of all attacks can be stopped using timely and actionable intelligence from their threat feeds.

“The deep, rich threat data delivered by Neustar’s UltraThreat Feeds service empowers users to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks,” added Kaczmarek.

The Ponemon report is based on survey responses from 1,025 IT security practitioners (70% of whom were at or above the supervisory level) in the U.S. and the U.K. whose organisations use threat data in their cybersecurity programmes or infrastructure. The most-represented industry was financial services (18% of respondents), followed by industrial and manufacturing (12%), retail (11%), public sector (11%), and health and pharmaceuticals (9%). Just over half of the participants were from organisations with a global headcount of more than 5,000 employees. The surveys were carried out in November 2020.

To access the full report, go to https://www.home.neustar/resources/whitepapers/state-of-threat-feed-effectiveness .

For more information about Neustar’s UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultrathreat-feeds . To learn more about Neustar’s full suite of security solutions, visit https://www.home.neustar/security-solutions .

-ENDS-

About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enable trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in marketing, risk, communications and security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye